SCHEMBL24637201

SCHEMBL24637201

COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC1CCN(CC(=O)C(C)C)CC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 12/20 0.82
EGFR P00533 13/20 0.73
EPHB4 P54760 2/20 0.61
GAK O14976 1/20 0.61
RIPK2 O43353 1/20 0.61
LYN P07948 1/20 0.61
RET P07949 1/20 0.61
EPHA1 P21709 1/20 0.61
ERBB3 P21860 1/20 0.61
EPHA2 P29317 1/20 0.61
EPHB2 P29323 1/20 0.61
EPHA5 P54756 1/20 0.61
EPHA4 P54764 1/20 0.61
ADK P55263 1/20 0.61
PTK6 Q13882 1/20 0.61
RIPK3 Q9Y572 1/20 0.61
AURKA O14965 1/20 0.61
INSR P06213 1/20 0.61
FBP1 P09467 1/20 0.61
PDGFRB P09619 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24637510 0.92 ERBB2 (0.86) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL29623469 0.91 ERBB2 (0.84) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL185530 0.91 ERBB2 (0.84) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL4885366 0.90 ERBB2 (1.00) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL1331718 0.90 ERBB2 (0.82) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL4879883 0.89 ERBB2 (0.81) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL29623426 0.88 EGFR (0.82) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL118379 0.88 EGFR (0.82) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL1446313 0.87 ERBB2 (0.78) ERBB2EGFREPHB4GAKRIPK2
SCHEMBL12743132 0.87 EGFR (0.81) ERBB2EGFREPHB4GAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220313829-A1 EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220313829-A1 EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF EGFR, ERBB2, ERBB3 ERBB2 2/4885EGFR 1/4885EPHB4 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.